Pediatrix Medical Group, Inc. $MD Shares Sold by CastleKnight Management LP

CastleKnight Management LP reduced its position in Pediatrix Medical Group, Inc. (NYSE:MD) by 41.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 396,066 shares of the company’s stock after selling 285,934 shares during the quarter. CastleKnight Management LP’s holdings in Pediatrix Medical Group were worth $8,472,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in MD. Victory Capital Management Inc. lifted its stake in shares of Pediatrix Medical Group by 30.7% in the 3rd quarter. Victory Capital Management Inc. now owns 4,126,207 shares of the company’s stock valued at $69,114,000 after purchasing an additional 968,553 shares during the period. American Century Companies Inc. lifted its stake in shares of Pediatrix Medical Group by 38.9% in the 3rd quarter. American Century Companies Inc. now owns 2,682,976 shares of the company’s stock valued at $44,940,000 after purchasing an additional 751,109 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in shares of Pediatrix Medical Group in the 4th quarter valued at $13,613,000. Ameriprise Financial Inc. lifted its stake in shares of Pediatrix Medical Group by 175.4% in the 2nd quarter. Ameriprise Financial Inc. now owns 744,473 shares of the company’s stock valued at $10,683,000 after purchasing an additional 474,186 shares during the period. Finally, BNP Paribas Financial Markets lifted its stake in shares of Pediatrix Medical Group by 669.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 476,098 shares of the company’s stock valued at $6,832,000 after purchasing an additional 414,216 shares during the period. 97.71% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have weighed in on MD shares. UBS Group upped their price objective on shares of Pediatrix Medical Group from $22.00 to $25.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 12th. Jefferies Financial Group restated a “buy” rating and set a $27.00 price objective on shares of Pediatrix Medical Group in a research report on Monday, April 20th. Weiss Ratings restated a “hold (c+)” rating on shares of Pediatrix Medical Group in a research report on Friday, March 27th. Truist Financial upped their price objective on shares of Pediatrix Medical Group from $21.00 to $23.00 and gave the stock a “hold” rating in a research report on Monday, April 13th. Finally, Mizuho set a $24.00 price objective on shares of Pediatrix Medical Group in a research report on Friday, May 8th. One investment analyst has rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, Pediatrix Medical Group has an average rating of “Hold” and a consensus target price of $22.50.

Pediatrix Medical Group Price Performance

Shares of NYSE MD opened at $23.56 on Thursday. The firm has a 50-day simple moving average of $22.58 and a 200-day simple moving average of $21.70. The stock has a market capitalization of $1.93 billion, a price-to-earnings ratio of 11.44 and a beta of 0.69. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 0.45. Pediatrix Medical Group, Inc. has a 52 week low of $11.84 and a 52 week high of $24.99.

Pediatrix Medical Group (NYSE:MD) last issued its earnings results on Tuesday, May 5th. The company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. The business had revenue of $476.20 million during the quarter, compared to analysts’ expectations of $465.83 million. Pediatrix Medical Group had a net margin of 9.02% and a return on equity of 19.94%. The company’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.33 earnings per share. On average, equities analysts predict that Pediatrix Medical Group, Inc. will post 2.1 earnings per share for the current fiscal year.

Insider Activity at Pediatrix Medical Group

In other news, Director Shirley A. Weis sold 36,028 shares of the stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $23.75, for a total value of $855,665.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.80% of the stock is owned by company insiders.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.